Sanofi Raises FY23 Guidance, Now Expects Business EPS To Grow By Mid-Single-Digit Versus Prior Expectation Of Low Single-Digit
Portfolio Pulse from Benzinga Newsdesk
Sanofi has revised its full-year 2023 business EPS guidance upward, now expecting it to grow by mid-single-digit at CER, barring unforeseen major adverse events. This includes an estimated €400 million of expected one-off COVID vaccine revenues in the second half of the year. However, the currency impact on 2023 business EPS is estimated between -6.5% to -7.5%.
July 28, 2023 | 7:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's upward revision of its FY23 business EPS guidance, including expected one-off COVID vaccine revenues, is a positive signal for investors. However, the estimated currency impact could offset some of the growth.
The upward revision of Sanofi's FY23 business EPS guidance indicates a positive outlook for the company's performance, which could drive its stock price up. The expected one-off COVID vaccine revenues also contribute to this positive outlook. However, the estimated currency impact could offset some of the growth, which investors need to consider.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100